Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
DHL has invested around €30mn ($30.81) in the new 12,621sqm site, which aims to serve over 4,200 regional customers.
With (almost) no fees and unlimited refunds for ATM charges, Novo business checking is a good option for small-business owners on the go. But Novo’s customer support is lacking, and you can’t ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Malaysia's capital, Kuala Lumpur, is facing a tax increase this year, according to news outlet The Star. Any change in the city would be implemented in phases, likely starting with industrial tax ...
Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn ...
The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine rivals continue to smooth over supply issues and rake in dividends from ...
The biggest talking point in the pharmaceutical industry at the moment revolves around treatments known as glucagon-like peptide-1 (GLP-1) agonists. GLP-1 agonists are used to treat diabetes and ...
Novo Nordisk should deliver a 24% CAGR over two years, driven by robust obesity drug market growth and improved operational performance, with an intrinsic value implying a 29% safety margin.
We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S (NYSE ...
KUALA LUMPUR, Dec 31 — In less than 24 hours, not only will the calendar change, but Malaysia will also witness the implementation of several important developments that will directly and indirectly ...
Novo Nordisk’s Phase 3 REDEFINE 1 study results for CagriSema have sparked a mixed reaction, with the drug achieving a 22.7% weight loss at 68 weeks, slightly edging out Lilly’s Zepbound at 22.5%.